64 related articles for article (PubMed ID: 26666823)
1. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Fu QH; Zhang Q; Zhang JY; Sun X; Lou Y; Li GG; Chen ZL; Bai XL; Liang TB
Tumour Biol; 2016 Jun; 37(6):7277-86. PubMed ID: 26666823
[TBL] [Abstract][Full Text] [Related]
2. Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Song CQ; Li Y; Mou H; Moore J; Park A; Pomyen Y; Hough S; Kennedy Z; Fischer A; Yin H; Anderson DG; Conte D; Zender L; Wang XW; Thorgeirsson S; Weng Z; Xue W
Gastroenterology; 2017 Apr; 152(5):1161-1173.e1. PubMed ID: 27956228
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Chen Y; Huang Y; Reiberger T; Duyverman AM; Huang P; Samuel R; Hiddingh L; Roberge S; Koppel C; Lauwers GY; Zhu AX; Jain RK; Duda DG
Hepatology; 2014 Apr; 59(4):1435-47. PubMed ID: 24242874
[TBL] [Abstract][Full Text] [Related]
4. Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Qiu YQ; Zhou J; Kang XS; Shen-Tu JZ; Ding LM; Tan FL; Guo J; Li LJ
Afr J Tradit Complement Altern Med; 2012; 9(3):431-9. PubMed ID: 23983378
[TBL] [Abstract][Full Text] [Related]
5. PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells.
Ho WS; Feldman MJ; Maric D; Amable L; Hall MD; Feldman GM; Ray-Chaudhury A; Lizak MJ; Vera JC; Robison RA; Zhuang Z; Heiss JD
Oncotarget; 2016 Mar; 7(11):12447-63. PubMed ID: 26799670
[TBL] [Abstract][Full Text] [Related]
6. Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair.
Ballout F; Lu H; Bhat N; Chen L; Peng D; Chen Z; Chen S; Sun X; Giordano S; Corso S; Zaika A; McDonald O; Livingstone AS; El-Rifai W
Clin Cancer Res; 2024 May; 30(10):2193-2205. PubMed ID: 38592373
[TBL] [Abstract][Full Text] [Related]
7. Phenotype-Based Screens with Conformation-Specific Inhibitors Reveal p38 Gamma and Delta as Targets for HCC Polypharmacology.
Yu JX; Craig AJ; Duffy ME; Villacorta-Martin C; Miguela V; Ruiz de Galarreta M; Scopton AP; Silber L; Maldonado AY; Rialdi A; Guccione E; Lujambio A; Villanueva A; Dar AC
Mol Cancer Ther; 2019 Sep; 18(9):1506-1519. PubMed ID: 31213506
[TBL] [Abstract][Full Text] [Related]
8. The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing.
Dias MH; Liudkovska V; Montenegro Navarro J; Giebel L; Champagne J; Papagianni C; Bleijerveld OB; Velds A; Agami R; Bernards R; Cieśla M
EMBO Rep; 2024 May; 25(5):2220-2238. PubMed ID: 38600345
[TBL] [Abstract][Full Text] [Related]
9. Enhancing Therapeutic Efficacy of Cisplatin by Blocking DNA Damage Repair.
Cong Y; Wang L; Wang Z; He S; Zhou D; Jing X; Huang Y
ACS Med Chem Lett; 2016 Oct; 7(10):924-928. PubMed ID: 27774130
[TBL] [Abstract][Full Text] [Related]
10. Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
Lin S; Hoffmann K; Gao C; Petrulionis M; Herr I; Schemmer P
J Pineal Res; 2017 Apr; 62(3):. PubMed ID: 28178378
[TBL] [Abstract][Full Text] [Related]
11. Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib.
Jiang Z; Dai C
J Hepatocell Carcinoma; 2023; 10():257-266. PubMed ID: 36815094
[TBL] [Abstract][Full Text] [Related]
12. Cellular Protein Phosphatase 2A Regulates Cell Survival Mechanisms in Influenza A Virus Infection.
Gerlt V; Mayr J; Del Sarto J; Ludwig S; Boergeling Y
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681823
[TBL] [Abstract][Full Text] [Related]
13. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects.
Tang W; Chen Z; Zhang W; Cheng Y; Zhang B; Wu F; Wang Q; Wang S; Rong D; Reiter FP; De Toni EN; Wang X
Signal Transduct Target Ther; 2020 Jun; 5(1):87. PubMed ID: 32532960
[TBL] [Abstract][Full Text] [Related]
14. PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer.
Fowle H; Zhao Z; Graña X
Adv Cancer Res; 2019; 144():55-93. PubMed ID: 31349904
[TBL] [Abstract][Full Text] [Related]
15. The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C.
D'Arcy BM; Swingle MR; Papke CM; Abney KA; Bouska ES; Prakash A; Honkanen RE
Mol Cancer Ther; 2019 Mar; 18(3):556-566. PubMed ID: 30679389
[TBL] [Abstract][Full Text] [Related]
16. Targeting PP2A in cancer: Combination therapies.
Mazhar S; Taylor SE; Sangodkar J; Narla G
Biochim Biophys Acta Mol Cell Res; 2019 Jan; 1866(1):51-63. PubMed ID: 30401535
[TBL] [Abstract][Full Text] [Related]
17. Primary tumor-derived exosomes facilitate metastasis by regulating adhesion of circulating tumor cells via SMAD3 in liver cancer.
Fu Q; Zhang Q; Lou Y; Yang J; Nie G; Chen Q; Chen Y; Zhang J; Wang J; Wei T; Qin H; Dang X; Bai X; Liang T
Oncogene; 2018 Nov; 37(47):6105-6118. PubMed ID: 29991801
[TBL] [Abstract][Full Text] [Related]
18. Targeting PP2A activates AMPK signaling to inhibit colorectal cancer cells.
Dai C; Zhang X; Xie D; Tang P; Li C; Zuo Y; Jiang B; Xue C
Oncotarget; 2017 Nov; 8(56):95810-95823. PubMed ID: 29221169
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells.
Liu T; Liu R; Zhang S; Guo K; Zhang Q; Li W; Liu Y
Oncol Lett; 2017 Jul; 14(1):517-524. PubMed ID: 28693200
[TBL] [Abstract][Full Text] [Related]
20. The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance.
Ruvolo PP
BBA Clin; 2016 Dec; 6():87-99. PubMed ID: 27556014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
